NCT00351325View on ClinicalTrials.gov

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Advanced Solid Malignancies
Interventions
DRUG

BMS-663513

mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks

Trial Locations (5)

15213

Magee-Womens Hospital Of Upmc, Pittsburgh

19104

University Of Pennsylvania Medical Center, Philadelphia

22908

University Of Virginia, Charlottesville

98109

University Of Washington, Seattle

M5G 2M9

Local Institution, Toronto

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00351325 - A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter